-+ 0.00%
-+ 0.00%
-+ 0.00%

Deutsche Bank Maintains Buy on Spyre Therapeutics, Lowers Price Target to $127

Benzinga·08/26/2026 18:01:38
Listen to the news
Deutsche Bank analyst David Hoang maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and lowers the price target from $135 to $127.